{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:06:05Z","timestamp":1784995565263,"version":"3.55.0"},"reference-count":119,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.pathol.2023.10.016","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T05:34:12Z","timestamp":1702532052000},"page":"228-238","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Predictive and prognostic biomarkers in urological tumours"],"prefix":"10.1016","volume":"56","author":[{"given":"Alessia","family":"Cimadamore","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Franzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Di Loreto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Blanca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Lopez-Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Crestani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Giannarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Puay Hoon","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedito A.","family":"Carneiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafik S.","family":"El-Deiry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodolfo","family":"Montironi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2023.10.016_bib1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib2","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib3","doi-asserted-by":"crossref","first-page":"S1159","DOI":"10.1016\/j.annonc.2020.08.2257","article-title":"696O_PR nivolumab\u00a0+ cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase III CheckMate 9ER trial","volume":"31","author":"Choueiri","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib4","doi-asserted-by":"crossref","first-page":"5794","DOI":"10.1200\/JCO.2008.21.4809","article-title":"Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor\u2013targeted agents: results from a large, multicenter study","volume":"27","author":"Heng","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib5","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00000478-200103000-00001","article-title":"Sarcomatoid differentiation in renal cell carcinoma","volume":"25","author":"de Peralta-Venturina","year":"2001","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2023.10.016_bib7","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1200\/JCO.2019.37.15_suppl.4500","article-title":"Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): outcomes in the combined IMDC intermediate\/poor risk and sarcomatoid subgroups of the phase 3 KEYNOTE-426 study","volume":"37","author":"Rini","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib8","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1200\/JCO.2019.37.15_suppl.4513","article-title":"CheckMate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in IMDC intermediate\/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features","volume":"37","author":"McDermott","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib9","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1038\/s41467-021-21068-9","article-title":"Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma","volume":"12","author":"Bakouny","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.10.016_bib10","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/s41585-020-00382-9","article-title":"Sarcomatoid renal cell carcinoma: biology, natural history and management","volume":"17","author":"Blum","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib11","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1073\/pnas.0406351101","article-title":"Costimulatory B7-H1 in renal cell carcinoma patients: indicator of tumour aggressiveness and potential therapeutic target","volume":"101","author":"Thompson","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pathol.2023.10.016_bib12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11523-015-0392-7","article-title":"Prognostic role of PD-L1 expression in renal cell carcinoma. a systematic review and meta-analysis","volume":"11","author":"Iacovelli","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib13","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3390\/cancers12071945","article-title":"The value of PD-L1 expression as predictive biomarker in metastatic renal cell carcinoma patients: a meta-analysis of randomized clinical trials","volume":"12","author":"Carretero-Gonz\u00e1lez","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2023.10.016_bib14","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.2174\/1389450121666200324151056","article-title":"PD1 and PD-L1 inhibitors for the treatment of kidney cancer: the role of PD-L1 assay","volume":"21","author":"Cimadamore","year":"2020","journal-title":"Curr Drug Targets"},{"key":"10.1016\/j.pathol.2023.10.016_bib15","article-title":"Characterization of tumour mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma","volume":"8","author":"Labriola","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2023.10.016_bib16","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-020-00729-2","article-title":"Burden of tumour mutations, neoepitopes, and other variants are weak predictors of cancer immunotherapy response and overall survival","volume":"12","author":"Wood","year":"2020","journal-title":"Genome Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib17","article-title":"Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis","volume":"8","author":"Dizman","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.pathol.2023.10.016_bib18","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma","volume":"26","author":"Braun","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib19","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1200\/JCO.2020.38.15_suppl.5009","article-title":"Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N+I) or sunitinib (S) in advanced renal cell carcinoma (aRCC)","volume":"38","author":"Motzer","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib20","first-page":"860","article-title":"von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma","volume":"180","author":"Choueiri","year":"2008","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib21","doi-asserted-by":"crossref","first-page":"5218","DOI":"10.1158\/1078-0432.CCR-13-0491","article-title":"The role of aberrant VHL\/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma","volume":"19","author":"Choueiri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib22","doi-asserted-by":"crossref","first-page":"13979","DOI":"10.18632\/oncotarget.14704","article-title":"Prognostic and predictive value of VHL gene alteration in renal cell carcinoma: a meta-analysis and review","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pathol.2023.10.016_bib23","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMoa2103425","article-title":"Belzutifan for renal cell carcinoma in von Hippel\u2013Lindau disease","volume":"385","author":"Jonasch","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib24","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.pathol.2023.10.016_bib25","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.10.016_bib26","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib27","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.ajhg.2013.04.012","article-title":"Germline BAP1 mutations predispose to renal cell carcinomas","volume":"92","author":"Popova","year":"2013","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.pathol.2023.10.016_bib28","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","article-title":"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2 : a report by MSKCC and the KIRC TCGA research network","volume":"19","author":"Hakimi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib29","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1001\/jamaoncol.2019.3158","article-title":"Clinical validation of PBRM1 alterations as a marker of immune checkpoint inhibitor response in renal cell carcinoma","volume":"5","author":"Braun","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib30","doi-asserted-by":"crossref","first-page":"5777","DOI":"10.1002\/cncr.27607","article-title":"Gain of chromosome 8q is associated with metastases and poor survival of patients with clear cell renal cell carcinoma","volume":"118","author":"Klatte","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.pathol.2023.10.016_bib31","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1038\/bjc.2014.420","article-title":"Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery","volume":"111","author":"El-Mokadem","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pathol.2023.10.016_bib32","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1038\/ncomms6135","article-title":"Variation in genomic landscape of clear cell renal cell carcinoma across Europe","volume":"5","author":"Scelo","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.10.016_bib33","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.cell.2018.03.057","article-title":"Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.10.016_bib34","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib35","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1001\/jamaoncol.2020.2218","article-title":"Efficacy of savolitinib vs sunitinib in patients with MET-driven papillary renal cell carcinoma","volume":"6","author":"Choueiri","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0140-6736(21)00152-5","article-title":"A\u00a0comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial","volume":"397","author":"Pal","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2023.10.016_bib37","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1470-2045(15)70167-1","article-title":"A\u00a016-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies","volume":"16","author":"Rini","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib38","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eururo.2014.02.035","article-title":"ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma","volume":"66","author":"Brooks","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1470-2045(10)70295-3","article-title":"Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study","volume":"12","author":"Cuzick","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085249","article-title":"Robust prognostic gene expression signatures in bladder cancer and lung adenocarcinoma depend on cell cycle related genes","volume":"9","author":"Dancik","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pathol.2023.10.016_bib41","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.eururo.2017.12.002","article-title":"A\u00a0multigene signature based on cell cycle proliferation improves prediction of mortality within 5 yr of radical nephrectomy for renal cell carcinoma","volume":"73","author":"Morgan","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib42","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.eururo.2018.03.033","article-title":"The cell cycle progression score: unclear role in renal cell carcinoma","volume":"74","author":"Ueno","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib44","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/2159-8290.CD-18-0957","article-title":"Transcriptomic profiling of the tumour microenvironment reveals distinct subgroups of clear cell renal cell cancer: data from a randomized phase III trial","volume":"9","author":"Hakimi","year":"2019","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.10.016_bib45","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1038\/s41591-020-1044-8","article-title":"Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN renal 101 trial","volume":"26","author":"Motzer","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib46","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/14712598.2023.2201371","article-title":"Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward","volume":"23","author":"Bil\u00e9-Silva","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.pathol.2023.10.016_bib47","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib48","doi-asserted-by":"crossref","first-page":"690","DOI":"10.21037\/atm.2019.10.24","article-title":"PD-L1 assessment in urothelial carcinoma: a practical approach","volume":"7","author":"Eckstein","year":"2019","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101925","article-title":"The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma","volume":"82","author":"Powles","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pathol.2023.10.016_bib50","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib51","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.pathol.2023.10.016_bib52","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 6","key":"10.1016\/j.pathol.2023.10.016_bib53","article-title":"Analysis of disease-free survival in CheckMate 274 by PD-L1 combined positive score and tumour proportion score","author":"Galsky","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib54","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","article-title":"Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study","volume":"23","author":"Siefker-Radtke","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib55","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pathol.2023.10.016_bib57","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4\u2013positive solid tumours, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib58","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib60","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance","volume":"29","author":"Kl\u00fcmper","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib61","doi-asserted-by":"crossref","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","article-title":"Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin","volume":"27","author":"Chu","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib62","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes","volume":"29","author":"Hoffman-Censits","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.pathol.2023.10.016_bib63","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib64","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.11.005","article-title":"TROP2 expression across molecular subtypes of urothelial carcinoma and enfortumab vedotin-resistant cells","volume":"5","author":"Chou","year":"2022","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib65","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1093\/annonc\/mdp488","article-title":"Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients","volume":"21","author":"La\u00e9","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrurol.2015.265","article-title":"Bladder cancer: a step closer to individualized treatment for bladder cancer","volume":"13","author":"Traboulsi","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib68","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.eururo.2015.07.009","article-title":"Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer","volume":"68","author":"Plimack","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib69","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1158\/2159-8290.CD-14-0623","article-title":"Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma","volume":"4","author":"Van Allen","year":"2014","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.10.016_bib70","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib71","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.euf.2022.04.001","article-title":"Using circulating tumour DNA to guide adjuvant therapy in bladder cancer: IMvigor010 and IMvigor011","volume":"8","author":"Grunewald","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.pathol.2023.10.016_bib72","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.10.016_bib73","doi-asserted-by":"crossref","first-page":"S721","DOI":"10.1016\/j.annonc.2021.08.112","volume":"32","author":"Powles","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib74","article-title":"Circulating tumour DNA as a predictive and prognostic biomarker in the perioperative treatment of muscle-invasive bladder cancer: a systematic review","author":"Crupi","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib75","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1200\/JCO.18.02052","article-title":"Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultradeep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma","volume":"37","author":"Christensen","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib76","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.eururo.2022.04.013","article-title":"Final results of neoadjuvant atezolizumab in cisplatin-ineligible patients with muscle-invasive urothelial cancer of the bladder","volume":"82","author":"Szabados","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib77","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/s41585-023-00725-2","article-title":"Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease","volume":"20","author":"Rose","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"Suppl 1","key":"10.1016\/j.pathol.2023.10.016_bib78","first-page":"S13","article-title":"The evolving landscape of prostate cancer somatic mutations","volume":"82","author":"Cotter","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.pathol.2023.10.016_bib79","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Robinson","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.pathol.2023.10.016_bib80","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/fon-2019-0745","article-title":"Germline and somatic mutations in prostate cancer: focus on defective DNA repair, PARP inhibitors and immunotherapy","volume":"16","author":"Cimadamore","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib81","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib82","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pathol.2023.10.016_bib83","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1200\/JCO.2021.39.6_suppl.126","article-title":"Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound","volume":"39","author":"De Bono","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib84","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1200\/JCO.20.01035","article-title":"Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration","volume":"38","author":"Abida","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib85","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-20-0394","article-title":"Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer: analysis from the phase II TRITON2 study","volume":"26","author":"Abida","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib86","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1158\/2159-8290.CD-21-0007","article-title":"Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial","volume":"11","author":"Carreira","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.10.016_bib87","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1038\/s41556-020-00586-6","article-title":"LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy","volume":"22","author":"Chen","year":"2020","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pathol.2023.10.016_bib88","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1003545","article-title":"Budding yeast ATM\/ATR control meiotic double-strand break (DSB) levels by down-regulating rec114, an essential component of the DSB-machinery","volume":"9","author":"Carballo","year":"2013","journal-title":"PLoS Genet"},{"key":"10.1016\/j.pathol.2023.10.016_bib89","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/s41467-017-00393-y","article-title":"Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer","volume":"8","author":"Asim","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.10.016_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aam7479","article-title":"Androgen receptor inhibitor\u2013induced \u201cBRCAness\u201d and PARP inhibition are synthetically lethal for castration-resistant prostate cancer","volume":"10","author":"Li","year":"2017","journal-title":"Sci Signal"},{"key":"10.1016\/j.pathol.2023.10.016_bib91","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-12-0120","article-title":"Dual roles of PARP-1 promote cancer growth and progression","volume":"2","author":"Schiewer","year":"2012","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pathol.2023.10.016_bib92","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200043","article-title":"Abiraterone and olaparib for metastatic castration-resistant prostate cancer","volume":"1","author":"Clarke","year":"2022","journal-title":"NEJM Evid"},{"key":"10.1016\/j.pathol.2023.10.016_bib93","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1200\/JCO.2022.40.6_suppl.012","volume":"40","author":"Chi","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib94","doi-asserted-by":"crossref","first-page":"LBA17","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA17","article-title":"TALAPRO-2: phase 3 study of talazoparib (TALA)\u00a0+ enzalutamide (ENZA) versus placebo (PBO)\u00a0+ ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Agarwal","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib95","doi-asserted-by":"crossref","first-page":"LBA16","DOI":"10.1200\/JCO.2023.41.6_suppl.LBA16","article-title":"Final overall survival (OS) in PROpel: abiraterone (abi) and olaparib (ola) versus abiraterone and placebo (pbo) as first-line (1L) therapy for metastatic castration-resistant prostate cancer (mCRPC)","volume":"41","author":"Clarke","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib96","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.eururo.2023.03.038","article-title":"PARP inhibitors for prostate cancer: tangled up in PROfound and PROpel (and TALAPRO-2) blues","volume":"84","author":"Beije","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib97","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/s41586-018-0291-z","article-title":"CRISPR screens identify genomic ribonucleotides as a source of PARP-trapping lesions","volume":"559","author":"Zimmermann","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.pathol.2023.10.016_bib98","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41467-023-35880-y","article-title":"CRISPR screens reveal genetic determinants of PARP inhibitor sensitivity and resistance in prostate cancer","volume":"14","author":"Tsujino","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.pathol.2023.10.016_bib99","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-20-4805","article-title":"Genomic analysis of circulating tumour DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms","volume":"27","author":"Tukachinsky","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib100","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.3390\/ijms22115522","article-title":"Circulating tumour DNA testing for homology recombination repair genes in prostate cancer: from the lab to the clinic","volume":"22","author":"Cimadamore","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.pathol.2023.10.016_bib101","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.3390\/cancers13194771","article-title":"Molecular characterization of prostate cancers in the precision medicine era","volume":"13","author":"Giunta","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2023.10.016_bib102","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1158\/1078-0432.CCR-22-0931","article-title":"Detection of BRCA1, BRCA2, and ATM alterations in matched tumour tissue and circulating tumour DNA in patients with prostate cancer screened in PROfound","volume":"29","author":"Chi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib103","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41572-018-0029-0","article-title":"Testicular cancer","volume":"4","author":"Cheng","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2023.10.016_bib104","article-title":"Advances in diagnosis and treatment of testicular cancer","volume":"379","author":"Chovanec","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.pathol.2023.10.016_bib105","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nrurol.2016.170","article-title":"The present and future of serum diagnostic tests for testicular germ cell tumours","volume":"13","author":"Murray","year":"2016","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib106","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1159\/000488284","article-title":"Testicular germ-cell tumours: a descriptive analysis of clinical characteristics at first presentation","volume":"100","author":"Dieckmann","year":"2018","journal-title":"Urol Int"},{"key":"10.1016\/j.pathol.2023.10.016_bib107","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.18.01480","article-title":"Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumours: results of a prospective multicentric study","volume":"37","author":"Dieckmann","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib108","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.eururo.2012.02.037","article-title":"Serum levels of microRNAs miR-371-3: a novel class of serum biomarkers for testicular germ cell tumours?","volume":"61","author":"Belge","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib109","first-page":"2709","article-title":"MicroRNAs in testicular cancer: implications for pathogenesis, diagnosis, prognosis and therapy","volume":"34","author":"Bezan","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1016\/j.pathol.2023.10.016_bib110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.urology.2016.07.037","article-title":"The evolving management of patients with clinical stage I seminoma","volume":"98","author":"Matulewicz","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.pathol.2023.10.016_bib111","first-page":"126","article-title":"Serum miRNA predicts viable disease after chemotherapy in patients with testicular nonseminoma germ cell tumour","volume":"200","author":"Le\u00e3o","year":"2018","journal-title":"J\u00a0Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib112","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.eururo.2021.06.006","article-title":"Circulating microRNAs, the next-generation serum biomarkers in testicular germ cell tumours: a systematic review","volume":"80","author":"Le\u00e3o","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib113","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1200\/JCO.20.03292","article-title":"Survival and new prognosticators in metastatic seminoma: results from the IGCCCG-update consortium","volume":"39","author":"Beyer","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib114","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting outcomes in men with metastatic nonseminomatous germ cell tumours (NSGCT): results from the IGCCCG update consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib115","doi-asserted-by":"crossref","first-page":"TPS5103","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS5103","article-title":"SWOG S1823\/CCTG GCC1: translational observational investigational study of the liquid biomarker microRNA 371a-3p in newly diagnosed germ cell tumours\u2014real-world trial design, rapid accrual, and robust secondary use of data opportunities","volume":"41","author":"Morin Coulombe","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pathol.2023.10.016_bib116","first-page":"163","article-title":"Serum level of microRNA-375-3p is not a reliable biomarker of teratoma","volume":"34","author":"Belge","year":"2020","journal-title":"In\u00a0Vivo (Brooklyn)"},{"key":"10.1016\/j.pathol.2023.10.016_bib117","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.eururo.2020.10.024","article-title":"Integrated expression of circulating mir375 and mir371 to identify teratoma and active germ cell malignancy components in malignant germ cell tumours","volume":"79","author":"Nappi","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.pathol.2023.10.016_bib118","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1172\/JCI41939","article-title":"Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer","volume":"120","author":"Koster","year":"2010","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.pathol.2023.10.016_bib119","doi-asserted-by":"crossref","first-page":"6247","DOI":"10.1002\/cam4.1871","article-title":"Long non-coding RNA H19 promotes TDRG1 expression and cisplatin resistance by sequestering miRNA-106b-5p in seminoma","volume":"7","author":"Wei","year":"2018","journal-title":"Cancer Med"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252300315X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252300315X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T16:32:26Z","timestamp":1758472346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130252300315X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":119,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S003130252300315X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.016","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictive and prognostic biomarkers in urological tumours","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2023.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}